ISA to Present at Business Conferences in May 2022

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

Long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor

ISA Pharmaceuticals to Attend Multiple In Person Conferences in Early 2022